Medicina de Família
Sequelas cardiopulmonares em pacientes recuperados de COVID-19: considerações para a atenção primária.
16 Jun, 2021 | 10:54hM-A | Distribuição do período de incubação da Covid-19 – “O período médio de incubação da COVID-19 foi de 5,2 a 7,2 dias, e o percentil 95 estaria entre 11 e 14,6 dias.”
16 Jun, 2021 | 10:53hPerspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”
16 Jun, 2021 | 10:52hA long-term perspective on immunity to COVID – Nature
França recomenda dose única de vacina caso uma infecção prévia por Covid seja detectada.
16 Jun, 2021 | 10:51hFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Relacionado: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. E Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Estudo randomizado | Breve aconselhamento + amostra grátis de reposição de nicotina + referenciamento ativo quase que dobram as chances de abandono do tabagismo entre pais fumantes.
16 Jun, 2021 | 10:46hBrief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial – JAMA Internal Medicine (gratuito por tempo limitado)
Revisão | Check-ups na atenção primária ao adulto.
16 Jun, 2021 | 10:44hGeneral Health Checks in Adult Primary Care: A Review – JAMA (gratuito por tempo limitado)
Editorial: The Routine General Medical Checkup: Valuable Practice or Unnecessary Ritual? – JAMA
Podcast: General Health Checks in Adult Primary Care
[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
Variante Delta do SARS-CoV-2 na Escócia: demografia, risco de admissão hospitalar e eficácia das vacinas – “O risco de admissão hospitalar por COVID-19 foi aproximadamente o dobro nos contaminados pela variante Delta em comparação aos contaminados pela variante Alfa.”
15 Jun, 2021 | 11:34hComentários: Delta may raise hospitalisation but vaccine still protects – UK Research and Innovation E Expert reaction to Lancet research letter analysing data from Scotland on the Delta variant, looking at demographics, risk of hospital admission and vaccine effectiveness – Science Media Centre
Comentário no Twitter (fio – clique para saber mais)
Just published @TheLancet
The #DeltaVariant experience in Scotlandhttps://t.co/IfjDJnCAMC
1. #VaccinesWork ("AZ appeared less effective than Pfizer")
2. Younger, unvaccinated got the delta infections
3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant pic.twitter.com/cP8clu57Rd— Eric Topol (@EricTopol) June 14, 2021
[Preprint] 2 doses de vacina contra Covid (Pfizer-BioNTech ou Oxford-AstraZeneca) são altamente eficazes contra hospitalização decorrente de infecção pela variante Delta.
15 Jun, 2021 | 11:32hComunicado de imprensa: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Comentário no Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— Public Health England (@PHE_uk) June 14, 2021
OMS: a variante Delta será dominante na Europa.
15 Jun, 2021 | 11:30hWHO official: Delta variant ‘poised to take hold’ in Europe – The Hill